Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

Health Secretary Robert F. Kennedy Jr. took aim at reputed journals such as the Lancet and said the agency will create ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster ...

Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

Small-cap stocks experienced a broad drawdown in Q1 with the Russell 2000® Growth Index (down 11.12%) trailing the Russell ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

The NIFTY MIDCAP 150's performance is influenced by the individual results of its constituent stocks. The declines in Bharat ...

Wall Street analysts issued a fresh round of ratings changes on Wednesday, including notable upgrades for State Street (STT) ...